NASDAQ:HLVX HilleVax (HLVX) Stock Price, News & Analysis $2.06 +0.01 (+0.49%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.06 0.00 (0.00%) As of 08/7/2025 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About HilleVax Stock (NASDAQ:HLVX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get HilleVax alerts:Sign Up Key Stats Today's Range$2.06▼$2.1050-Day Range$1.85▼$2.1752-Week Range$1.34▼$2.17Volume1.38 million shsAverage Volume741,005 shsMarket Capitalization$103.29 millionP/E RatioN/ADividend YieldN/APrice Target$2.00Consensus RatingHold Company Overview HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts. Read More HilleVax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreHLVX MarketRank™: HilleVax scored higher than 38% of companies evaluated by MarketBeat, and ranked 740th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingHilleVax has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHilleVax has received no research coverage in the past 90 days.Read more about HilleVax's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for HilleVax are expected to grow in the coming year, from ($2.64) to ($1.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHilleVax has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about HilleVax's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.02% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently decreased by 39.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.02% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in HilleVax has recently decreased by 39.40%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.25 News SentimentHilleVax has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for HilleVax this week, compared to 1 article on an average week.MarketBeat Follows1 people have added HilleVax to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have not sold or bought any company stock.Percentage Held by Insiders24.90% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.42% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about HilleVax's insider trading history. Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address HLVX Stock News Headlines$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)August 7 at 6:34 PM | prnewswire.comHilleVax Reports Second Quarter 2025 Financial ResultsAugust 6 at 4:05 PM | globenewswire.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account. | Weiss Ratings (Ad)HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVXAugust 5 at 9:20 PM | businesswire.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.August 5 at 6:01 PM | prnewswire.comShareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public ShareholdersAugust 4, 2025 | prnewswire.comHLVX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of HilleVax, Inc. Is Fair to ShareholdersAugust 4, 2025 | businesswire.comKosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market SessionAugust 4, 2025 | benzinga.comSee More Headlines HLVX Stock Analysis - Frequently Asked Questions How have HLVX shares performed this year? HilleVax's stock was trading at $2.07 at the start of the year. Since then, HLVX shares have decreased by 0.5% and is now trading at $2.06. How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) announced its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. When did HilleVax IPO? HilleVax (HLVX) raised $200 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share. Who are HilleVax's major shareholders? Top institutional investors of HilleVax include Y Intercept Hong Kong Ltd (0.22%). Insiders that own company stock include Life Sciences X LP Frazier, Aditya Kohli, Astrid Borkowski, Shane Maltbie and Sean Mcloughlin. View institutional ownership trends. How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of HilleVax own? Based on aggregate information from My MarketBeat watchlists, some other companies that HilleVax investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings8/06/2025Today8/07/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HLVX CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for HilleVax$2.00 High Price Target$2.00 Low Price Target$2.00 Potential Upside/Downside-2.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$147.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-51.86% Return on Assets-41.45% Debt Debt-to-Equity RatioN/A Current Ratio25.32 Quick Ratio25.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book0.66Miscellaneous Outstanding Shares50,140,000Free Float37,656,000Market Cap$103.29 million OptionableNot Optionable Beta0.77 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:HLVX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HilleVax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.